Vaxcyte, Inc. Annual Report: A Deep Dive into Their Year

Welcome to a clear and concise overview of Vaxcyte, Inc.'s performance and future strategy. This summary, based on their annual filing for the fiscal year ended December 31, 2025, explains their mission, financial health, pipeline progress, and what lies ahead – all in straightforward language for every investor.

Business Overview: Vaxcyte's Mission: Pioneering Vaccines for Global Health

Vaxcyte is a biotech company focused on developing new vaccines to address serious health challenges. They use their unique protein conjugate and synthetic biology technologies to create more effective and broader-acting vaccines, especially for infectious diseases. The company aims to revolutionize vaccine development through precision and potency, primarily by advancing its leading vaccine candidates through clinical trials toward potential market launch.

Financial Performance: A Year of Strategic Investment and Growth

For the year ending December 31, 2025, Vaxcyte significantly invested in its research and development pipeline. This is typical for companies in the clinical trial phase.

• Revenue: Vaxcyte reported $25 million in collaboration revenue, mainly from milestone payments tied to research agreements. This represents a 25% increase from the previous year, reflecting progress in their early-stage programs.
• Net Loss: As expected for a development-stage biotech, Vaxcyte recorded a net loss of $280 million for the year, up from a $220 million net loss in 2024. This larger loss directly resulted from accelerated investment in clinical trials and manufacturing scale-up.
• Research & Development (R&D) Expenses: R&D remained the largest expense, totaling $250 million, an increase from $190 million in 2024. This substantial investment highlights their commitment to moving their lead vaccine candidates through clinical development.

Management's Discussion and Analysis (MD&A) Highlights

Management noted that the rise in collaboration revenue reflects successfully reaching certain preclinical and early clinical milestones under existing agreements, which validates the company's technology platform.

The expanded net loss and increased R&D expenses directly stem from Vaxcyte's strategic decision to speed up the development of its key programs. This includes advancing VAX-24 into Phase 2 and starting Phase 1 for VAX-31. Management considers these investments essential for progressing the pipeline and ultimately achieving the long-term value of the company's assets.

Vaxcyte continues to prioritize spending on clinical development, preparing for manufacturing, and expanding its proprietary technology platforms. The company's financial strategy focuses on maintaining a strong cash position to support these ambitious development timelines and avoid needing to raise money by selling more shares in the near term.

Financial Health: Strong Cash Position and Liquidity

Vaxcyte ended the year with a robust cash, cash equivalents, and marketable securities balance of approximately $650 million. Successful fundraising activities during the year strengthened this position.

• In March 2025, the company completed a Follow-On Public Offering, raising $200 million to fund the expansion of its clinical programs.
• Vaxcyte also used an At-The-Market (ATM) Offering program throughout the year, raising an additional $75 million as opportunities arose to support general corporate purposes.

These funding strategies are crucial for maintaining operational stability and advancing their ambitious pipeline without significant debt. Based on current spending rates, this cash position provides enough funds to operate into late 2027. The company takes a conservative approach to debt, holding no significant long-term debt obligations, which ensures financial flexibility. Management believes current capital resources are sufficient to fund planned operations for the foreseeable future, though future capital raises will be necessary to support later-stage clinical trials and potential market launch.

Competitive Position

The vaccine market is highly competitive and rapidly changing. It features intense research and development efforts from both large, established pharmaceutical companies and smaller, innovative biotech firms. Key competitors include major pharmaceutical companies with significant resources, extensive commercial networks, and diverse vaccine portfolios (e.g., Pfizer, Merck, GSK, Sanofi), as well as other biotech companies developing new vaccine technologies.

Companies compete based on factors such as product effectiveness, safety, breadth of coverage, ease of administration, manufacturing capabilities, intellectual property protection, and market access.

Vaxcyte believes its proprietary protein conjugate and synthetic biology platforms offer a competitive edge. These platforms enable the development of vaccines with potentially improved immune responses, broader protection, and more efficient manufacturing compared to traditional methods. By focusing on serious health challenges like pneumococcal disease and Group A Streptococcus, Vaxcyte targets areas with high clinical and commercial potential. However, competitors may develop alternative or superior products, or achieve regulatory approval and market penetration more quickly.

Risk Factors: Risks and Challenges Ahead

Investors should understand the natural risks in the biotechnology sector:

• Clinical Trial Success: Vaxcyte cannot guarantee the success of VAX-24 and other pipeline candidates. Clinical trials are complex, costly, and can fail at any stage due to issues with effectiveness, safety, or other factors.
• Regulatory Approval: Even with positive clinical data, obtaining regulatory approval from agencies like the FDA is a lengthy and uncertain process, and approval is never guaranteed.
• Competition: The vaccine market is highly competitive. Established players and other innovative companies developing similar products could impact Vaxcyte's market share and pricing power.
• Funding Needs: While currently well-capitalized, Vaxcyte will need substantial additional funding to complete clinical trials, secure regulatory approvals, and bring its products to market. Future financing may dilute existing shareholders.
• Manufacturing & Supply Chain: Scaling up manufacturing for commercial launch presents significant challenges, including ensuring consistent quality, sufficient supply, and managing complex global supply chains.
• Intellectual Property: Protecting their proprietary technology through patents and other means is crucial for long-term success. There is a risk of patent challenges or an inability to obtain adequate protection.
• Product Liability: As a pharmaceutical company, Vaxcyte faces inherent product liability risks associated with developing and selling vaccines.

Future Outlook: Outlook and Strategic Priorities for 2026

Looking ahead, Vaxcyte's strategic priorities for 2026 include:

• Starting the crucial Phase 3 trial for VAX-24, a key step toward potential regulatory submission.
• Reporting initial safety and immune response data for VAX-31 Phase 1, which will guide its further development.
• Advancing preclinical programs and selecting new development candidates to refresh and expand the pipeline.
• Continuing to strengthen manufacturing capabilities and supply chain partnerships in preparation for VAX-24's potential market launch.
• Maintaining a strong financial position to support ongoing research and development and operational activities.

Pipeline Progress: Advancing Key Vaccine Candidates

Vaxcyte made significant progress in its clinical pipeline during 2025:

• VAX-24 (Pneumococcal Conjugate Vaccine): This lead candidate, designed to prevent pneumococcal disease, successfully completed its Phase 2 clinical trial in adults. Vaxcyte released topline data in Q4 2025, which demonstrated strong immune responses and a favorable safety profile across all dose groups, meeting primary goals. The company is on track to start a Phase 3 pivotal trial in Q3 2026, a critical step toward potential regulatory approval.
• VAX-31 (Group A Strep Vaccine): Their next-generation vaccine candidate for Group A Streptococcus infections entered Phase 1 clinical trials in Q2 2025. Vaxcyte expects initial safety data in mid-2026.
• Preclinical Programs: Vaxcyte continues to advance several preclinical programs, including candidates for Shigella and other infectious diseases. They plan to select a new development candidate for studies needed before human trials in early 2027.

Key Partnerships & Operational Developments

Vaxcyte continues to strengthen its operational foundation and strategic alliances.

Commercial manufacturing and supply agreements with Lonza and Patheon are critical. These partnerships provide Vaxcyte with access to specialized facilities and expertise for large-scale production of their vaccine candidates, especially as VAX-24 moves closer to potential market launch.

Their ongoing collaboration with the National Institutes of Health (NIH) and participation in the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) program highlight their commitment to addressing global health threats. CARB-X offers non-dilutive funding and expertise to accelerate the development of innovative solutions against drug-resistant bacteria, validating Vaxcyte's scientific approach.

The company established a New Corporate Headquarters Facility in Q1 2025, consolidating operations and providing expanded laboratory and office space to support its growing team and pipeline. This move, along with related sublease agreements, reflects their long-term growth trajectory.

Vaxcyte maintains its status as a "well-known seasoned issuer" and a "large accelerated filer," signifying its established presence and adherence to rigorous SEC reporting standards. The company continues to attract and retain top talent through comprehensive Equity Incentive Plans and an Employee Stock Purchase Plan, offering stock options, restricted stock units (RSUs), and phantom share units (PSUs) to ensure employees' goals align with shareholders' goals.

In summary, 2025 was a year of significant investment and clinical progress for Vaxcyte. While substantial risks remain, particularly in clinical development and regulatory pathways, the company's strong cash position and advancing pipeline position it for a potentially transformative 2026.